Open Call SC1-HCO-10-2016: Support for Europe's Leading Health ICT SMEs
The business environment and sustainable business models for eHealth SMEs have been a major challenge when introducing innovations in new healthcare delivery. The scope is co-ordinating post R&D and offering support for developing business models, improving the maturity of the new products emerging from Europe's leading Health ICT SMEs, developing a pro-innovation approach to address legal conditions in Europe and globally on a case-by-case basis.
Read more ...
Open Call H2020-SMEINST-1-2015: Horizon 2020 Dedicated SME Instrument Phase 1 and 2
The dedicated SME instrument's supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target.
Read more ...
Open Call H2020-ISSI-2015-1 for Integrating Society in Science and Innovation (ISSI-4-2015: On-Line Mechanisms for Knowledge-Based Policy Advice)
In a global perspective Europe can gain from effective knowledge-based decision-making, widening its knowledge base beyond science, not the least with regard to science, technology and innovation (STI) governance itself.
Read more ...
Open Call H2020-ISSI-2015-1 for Integrating Society in Science and Innovation (ISSI-3-2015: Knowledge Sharing Platform)
Evidence from Sixth Framework Programme Science and Society (S&S) and Seventh Framework Programme Science in Society (SiS) programmes shows that more consistent policy development in Science and Technology requires systematic cooperation and a shared knowledge base on which European, national and sub-national research and innovation policy decisions can be drawn from.
Read more ...
IMI Call for Proposals with Focus on Alzheimer's Disease, Diabetes, Patient Involvement
The Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines.
Read more ...
H2020-FETOPEN-2014-2015-RIA Open Call: Novel Ideas for Radically New Technologies
Supporting a large set of early stage, high risk visionary science and technology collaborative research projects is necessary for the successful exploration of new foundations for radically new future technologies. Nurturing fragile ideas requires an agile, risk-friendly and highly interdisciplinary research approach, expanding well beyond the strictly technological disciplines.
Read more ...
Helmsley Charitable Trust Announces $5 Million Request for Proposals for Innovative uses of Type 1 Diabetes Data
The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced the launch of the Diabetes Data Innovation Initiative. The Trust has issued a request for proposals to identify high-potential projects and pioneering digital health solutions that could enable the integration of diabetes data to identify trends and develop personalized patient guidance and decision support for providers.
Read more ...
The business environment and sustainable business models for eHealth SMEs have been a major challenge when introducing innovations in new healthcare delivery. The scope is co-ordinating post R&D and offering support for developing business models, improving the maturity of the new products emerging from Europe's leading Health ICT SMEs, developing a pro-innovation approach to address legal conditions in Europe and globally on a case-by-case basis. 
The Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines.